

**SCEPTRE****SCEPTRE MEDICAL (INDIA) LIMITED****Corporate Identity Number: U33112DL2010PLC204626**

REGISTERED OFFICE	CONTACT PERSON	TELEPHONE AND EMAIL	WEBSITE
Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-III, North West Delhi, Delhi – 110052, India.	Vidushi Company Secretary and Compliance Officer	Tel No: 011 4155 8987 Email Id: cs@sceptremedical.com	www.sceptremedical.com

PROMOTERS OF OUR COMPANY: SANJAY MANOCHA, YOGESH SACHDEVA, KARTIK PALTA, SUKESH ARORA, ARCHNA MANOCHA, MONA SACHDEVA, CHARU PALTA AND SIDDHARTH MANOCHA

DETAILS OF THE OFFER TO THE PUBLIC

TYPE	FRESH ISSUE SIZE (IN ₹ LAKHS)	OFFER FOR SALE SIZE	TOTAL OFFER SIZE	ELIGIBILITY AND SHARE RESERVATION AMONG QIB, NIB & II
Fresh Issue and Offer for sale	Up to 56,00,000* Equity Shares of face value of ₹ 10 each aggregating to ₹ [●] Lakhs	Up to 13,00,000* Equity Shares of face value of ₹ 10 each aggregating to ₹ [●] Lakhs	Up to 69,00,000* Equity Shares of face value of ₹ 10 each aggregating to ₹ [●] Lakhs	The offer is being made in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 through Book Building Process in accordance with Regulation 229(2) and 253(1) of the SEBI ICDR Regulations. For further details, see “Other Regulatory and Statutory Disclosures - Eligibility of the Offer” on page 309. For details in relation to share reservation among QIBs, NIIs and IIs, see “Offer Structure” on page 334.

* Subject to finalisation of basis of allotment

DETAILS OF OFFER FOR SALE BY SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION

NAME OF THE SELLING SHAREHOLDERS	TYPE	NUMBER OF EQUITY SHARES OFFERED	WEIGHTED AVERAGE COST OF ACQUISITION PER EQUITY SHARE (IN ₹)*
Archna Manocha	Promoter selling shareholder	Up to 5,20,000	Nil
Mona Sachdeva	Promoter selling shareholder	Up to 3,64,000	6.15
Charu Palta	Promoter selling shareholder	Up to 2,60,000	6.15
Sukesh Arora	Promoter selling shareholder	Up to 1,56,000	6.15
Manas Gupta (KRadhe Enterprises)	Investor selling shareholder	Up to 87,000	Nil
Amit Kumar Saraogi (Murli Janki Legacy Ventures)	Investor selling shareholder	Up to 87,000	18.11
Neeru Gupta (Radhesh Enterprises)	Investor selling shareholder	Up to 87,000	12.62
Amit Gupta (Wealth Creators)	Investor selling shareholder	Up to 87,000	12.62

*As certified by Surender Kumar Singhal & Co., Chartered Accountants, by way of their certificate dated September 29, 2026

RISK IN RELATION TO THE FIRST OFFER

This being the first public offer of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is ₹ 10 each. The Floor Price, the Cap Price and the Offer Price to be determined by our Company in consultation with the Book Running Lead Manager in accordance with SEBI ICDR Regulations and on the basis of the assessment of market demand for our Equity Shares by way of the Book Building Process, as disclosed in “Basis of the Offer Price” on page 121 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after Listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to section titled “Risk Factors” appearing on page 20 of this Draft Red Herring Prospectus.

ISSUER’S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the information contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.

LISTING

The Equity Shares Offered through this Draft Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited (“BSE SME”) in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received “in-principle” approval letter dated [●] from BSE for using its name in the Red Herring Prospectus / Prospectus for listing of our shares on the SME Platform of BSE Limited. For the purpose of this

Offer, the Designated Stock Exchange will be the BSE Limited.

BOOK RUNNING LEAD MANAGER TO THE OFFER

NAME AND LOGO

CONTACT PERSON

EMAIL & TELEPHONE



**UNISTONE CAPITAL PRIVATE
LIMITED**

Rinku Vora/ Shruti
Shah

Email: mb@unistonecapital.com
Tel. No: +91 224 604 6494

REGISTRAR TO THE OFFER

NAME AND LOGO

CONTACT PERSON

EMAIL & TELEPHONE



**BEETAL FINANCIAL &
COMPUTER SERVICES
PRIVATE LIMITED**

Punit Mittal

Email: beetalrta@gmail.com; beetal@beetal.in
Tel. No: 011-42959000-09

BID/OFFER PERIOD

**ANCHOR
PERIOD⁽¹⁾: [●]**

**INVESTOR BID/
OFFER**

BID/OFFER OPENS ON⁽¹⁾: [●]

BID/OFFER CLOSES ON⁽²⁾⁽³⁾: [●]

- (1) Our Company may in consultation with the BRLM may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.
- (2) Our Company may, in consultation with the BRLM, consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.
- (3) The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Offer Closing Day.

IN THE NATURE OF DRAFT ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE DRAFT RED HERRING PROSPECTUS

 Please scan this QR code to view the Draft Red Herring Prospectus and the Draft Abridged Prospectus	The following is a general summary of certain disclosures in the Draft Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Draft Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Draft Red Herring Prospectus, which is available at the websites of BSE Limited at www.bseindia.com, the Company at www.sceptremedical.com and the BRLM at www.unistonecapital.com. References below to page numbers are to page numbers of the Draft Red Herring Prospectus dated September 30, 2026. Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the Draft Red Herring Prospectus.
--	---

1. Summary of the Primary business

We are engaged in the business of manufacturing, developing and supplying healthcare consumables, including infection control products, health and hygiene products and medical devices. We offer a diversified product portfolio comprising of antiseptics and disinfectants, procedural consumables and wipes and single-use medical devices, which serve a range of therapeutic and clinical applications across renal care, critical care, intensive care urology care and oncology care.

a) Business Overview – Products and Services

Our infection control products are utilized for application in skin preparation, patient hygiene, surface and instrument disinfection, and other infection control applications that form an integral part of routine medical operations. Our health and hygiene product offerings include multipurpose wipes, patient wipes, cosmetic wipes, baby wipes, and other products, which cater to personal care, medical and cleansing requirements. Our medical device portfolio includes vascular access catheters, disposable biopsy instruments, skin staples, hemodialysis catheters, AV fistula needle, introducer needles, guidewires, transducer protectors, disposable hemodialysis tubing sets, among other products. Our medical devices are used in a range of clinical procedures such as dialysis treatment, vascular access, transfusion therapy, procedural kits and surgical interventions, where adherence to hygiene and sterilization standards is essential for patient safety and clinical care.

b) Description of industries served and typical customers

We serve primarily to the Healthcare and Health & Hygiene Industries. We are currently catering to B2B, B2D, D2C and B2G segment.

c) Segment Reporting and Revenue Contribution

Our Company operates in single segment i.e. Healthcare. Our revenue from operations for fiscals 2026, 2025 and 2024 was ₹ 6,794.51 lakhs, ₹ 2,869.45 lakhs and ₹ 2,223.72 lakhs respectively.

d) Key Geographies Served:

Our Company derives revenue from both domestic and export markets, enabling us to cater to customers across multiple geographies and product applications. In India, we operate across multiple states including Delhi, Uttar Pradesh, Haryana, Uttarakhand, Maharashtra, Rajasthan, Punjab, Gujarat, West Bengal, Telangana, Karnataka, Kerala and other states, indicating a geographically diversified domestic customer base. We currently export our products to several countries, including Nepal, USA, Germany, Botswana, Australia and Qatar.

e) Revenue concentration among top 5 customers

The % of contribution of our Company's customers vis-à-vis the total revenue from operations respectively for the Fiscal 2026, 2025 and 2024 is as follows:

Particulars	Top Customers as a percentage (%) of total revenue		
	Fiscal 2026	Fiscal 2025	Fiscal 2024
Top 5	25.35%	68.33%	66.61%
Top 10	34.08%	76.93%	78.12%

f) Key Facilities

Our Registered Office is located at Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase-III, NorthWest Delhi, Delhi-110052, India. We operate through three existing and one Proposed manufacturing facilities located in Sonipat, Haryana which are as follows:.

Unit	Address	Usage
Facility I	230- 231, HSIIDC, Rai Industrial Area, Rai, Sonipat-131029, Haryana, India	Manufacturing
Facility II	31, HSIIDC, Rai Industrial Area, Rai, Sonipat-131029, Haryana, India	Manufacturing
Facility III	Plot No. 187, Sector-38, Phase I, HSIIDC, Rai, Sonipat – 131029, Haryana, India	Manufacturing
Facility IV	Killa No 19/5, Khewat 100, Liwan Main Road, Mapsko Garden Estates, Liwan Village, Sonipat, Haryana – 131001, India	Proposed Manufacturing

g) Business Strengths and Strategies

Strengths:

- 1) Experienced Promoters and senior management team.
- 2) Large and long-standing customer base
- 3) Strong portfolio and diverse range of products
- 4) Robust Pan-India Distribution Network.
- 5) Quality Assurance.

Strategies:

- 1) Setting Up Plant and Machinery at the New Manufacturing Facility.
- 2) Leveraging Import Substitution and “Make in India” for Growth
- 3) Expansion to Strengthen Market Presence
- 4) Strengthening Operational Capabilities and Efficiency

For further and complete information please refer chapter titled “Our Business” on page no 161 of the DRHP.

2. Summary of the Industry

Healthcare is one of the world's largest and fastest-evolving industries, supported by rising life expectancy, an ageing population, increasing prevalence of chronic diseases, rapid technological advancements and growing public and private healthcare expenditure. The industry encompasses hospitals, diagnostics, pharmaceuticals, biotechnology, medical devices, digital health, healthcare information technology and preventive care services. Rising healthcare awareness, expanding health insurance coverage and greater focus on early diagnosis and preventive care continue to drive demand for healthcare services across developed and emerging economies.

Demographic changes are expected to remain a key long-term driver of global healthcare demand. Increasing life expectancy, population ageing and the growing burden of non-communicable diseases—including cardiovascular diseases, diabetes, cancer and respiratory disorders—are increasing the need for hospitals, diagnostics, pharmaceuticals, rehabilitation and long-term care services. At the same time, expanding urbanisation, improving healthcare access in emerging markets and rising disposable incomes are supporting greater utilisation of healthcare services worldwide.

For further information, see “Industry Overview” beginning on page 134 of the DRHP.

3. Promoters

Sanjay	Sanjay Manocha aged 57 years is the Promoter and Managing Director of our Company. He has been
---------------	--

Manocha	associated with our company since its inception i.e. June 24, 2010. He holds a Bachelor of Commerce degree from University of Delhi. Prior He has been serving as a director of both our subsidiaries, Manocha Medicals Private Limited which was later renamed to Sceptre Medical Devices Private Limited since January 2002 and M. S. Medicals Private Limited since March 2008. He has an overall 23 years of experience in healthcare and hygiene industry. He is responsible for leading the company's business development initiatives, including identifying growth opportunities, fostering strategic partnerships, expanding market presence, and driving revenue generation.
Yogesh Sachdeva	Yogesh Sachdeva aged 51 years is the Promoter and Whole-Time Director of our company. He has been associated with our Company since January 01, 2025. He completed his Senior Secondary education in 1992 from Ravindra Public School, Pitampura, Delhi. He has been serving as a director of both our subsidiaries, Manocha Medicals Private Limited which was later renamed as Sceptre Medical Devices Private Limited since January 2016 and M. S. Medicals Private Limited since March 2008. He has over 17 years of experience in medical devices industry. He has been responsible for developing and implementing marketing strategies, identifying business opportunities, analysing market trends, providing strategic guidance on capital expenditure, and supporting the Company's long-term business growth and expansion initiatives.
Kartik Palta	Kartik Palta aged 62 years is the Promoter and Whole-Time Director of our Company. He has been associated with our company since January 01, 2025. He holds a Bachelor's degree in Mechanical Engineering from University of Mysore. Prior to joining our company, he was associated with Hindustan Syringes and Medical Devices Ltd as Plant Manager from November 1992 till October 2002, with Bio Med Health Care Products Pvt Ltd as General Manager – Operations from November 2002 till November 2007 and served as a Director of Ilife Medical Devices Pvt Ltd from December 2007 till March 2020. He has been serving as a director of both our subsidiaries, Manocha Medicals Private Limited, which was later renamed to Sceptre Medical Devices Private Limited since January 2016 and M. S. Medicals Private Limited since July 2024. He has over 33 years of experience in medical devices industry. He is responsible for overseeing the operational efficiency of the Company's product development, streamlining manufacturing and operational processes, and implementing strategies to enhance operational effectiveness and overall organizational performance.
Sukesh Arora	Sukesh Arora aged 50 years is one of the Promoter of our Company. He has completed Senior Secondary from Delhi. He has been associated with our company as Director since January 01, 2025 and served as a director till June 25, 2025. He has been serving as a director of both our subsidiaries, which is Sceptre Medical Devices Private Limited since June 2025 and M. S. Medicals Private Limited since July 2024. Currently, he is the Chief Operating Officer (COO) of our company and he is responsible for overseeing sales, logistics, dispatch and inventory management functions for our subsidiaries.
Archna Manocha	Archna Manocha aged 56 years is the Promoter and Chief Financial Officer of our Company. She has been associated with our company since August 03, 2011. She holds a Bachelor of Commerce degree from University of Delhi. She served as a Director in Sceptre Medical Devices Private Limited from January 2008 till January 2016 and M. S. Medicals Private Limited from June 2015 till July 2024. She has over 17 years of experience in finance and accounting. She is responsible for formulating and implementing the Company's financial strategy, overseeing financial governance, planning and management, and supervising regulatory compliance.
Mona Sachdeva	Mona Sachdeva aged 46 years is one of the Promoter of our Company. She holds Bachelor of Commerce from University of Delhi. She is associated with our Company since 2024. She served as a Director in M. S Medicals Private Limited from June 2015 till July 2024. She has an overall experience of more than 11 years in healthcare industry. She is responsible for overseeing financing activities and accounting in M. S. Medicals Pvt Ltd.
Charu Palta	Charu Palta aged 58 years is one of the Promoters of the Company. She holds a Master of Business Administration in Marketing Management from Indira Gandhi National Open University. She is associated with our Company since 2024. She was previously associated with LIC Housing Finance Ltd as Assistant Manager from July 1992 till May 2006. She has an overall experience of 15 years in housing finance, financial operations, customer relationship management and business development. She brings experience in managing business operations and supporting the overall functioning of the organisation.
Siddharth Manocha	Siddharth Manocha aged 31 years is one of the Promoters of our Company. He holds an Integrated Bachelor of Administration and Bachelor of Law degree from Guru Gobind Singh Indraprastha University. He has been associated with our company since 2018 as Chief Business Officer. He is also serving as a director in Sceptre Hygiene Private Limited since March 2026. He is also a designated partner in Organic Wipes LLP since July 2021. He is responsible for business development, quality oversight, supply chain coordination and marketing strategy for Health & Hygiene division.

For details, see “Our Promoters and Promoter Group” and “Our Management” on page 231 and 214 of the DRHP.

4. Objects of the Offer

Requirements of funds and utilization of Net Proceeds

(₹ in lakhs)

Sr. No.	Particulars	Estimated utilization from Net Proceeds
1.	Funding requirement for the purchase of machinery and equipment and the development of clean Room for Production facility for the new manufacturing facility located in Sonipat, Haryana – 131001, India (“ Proposed Facility ”);	3,152.35
2.	Funding requirement towards product registrations in international markets, along with related and ancillary activities	221.18
3.	Repayment and/or pre-payment, in part or full, of certain borrowings availed by our Company	400.00
4.	General Corporate Purposes ⁽¹⁾	[●]
	Total ⁽¹⁾⁽²⁾	[●]

⁽¹⁾To be finalized upon determination of the Offer price and updated in the Prospectus prior to filing with the RoC. The amount utilized for general corporate purposes shall not exceed 15% of the Gross Proceeds of the Offer, or ₹ 1000.00 lakhs, whichever is lower.

⁽²⁾Our Board, at its meeting held on September 29, 2026 has approved the proposed objects of the Offer and the respective amounts proposed to be utilized from Net Proceeds for each object.

5. Aggregate pre-offer and post-offer shareholding of promoters, members of the promoter group and top 10 shareholders

The aggregate shareholding of each of our Promoters, members of our Promoter Group and additional top 10 shareholders (apart from our Promoters and Promoter Group) as on the date of the Price Band advertisement publication and as at the date of Allotment is set forth below:

Sr. No.	Pre-Offer shareholding as on date of the Price Band Advertisement*			Post-Offer Shareholding as at Allotment*			
				At the lower end of the price band (₹[●])		At the upper end of the price band (₹[●])	
	Name of the Shareholder	Number of Equity Shares [^]	Pre-Offer shareholding on a fully diluted basis (%) [^]	Number of Equity Shares*	Post-Offer shareholding on a fully diluted basis (%)*	Number of Equity Shares*	Post-Offer shareholding on a fully diluted basis (%)*
Promoters							
1.	Sanjay Manocha	38,08,818	21.75%	[●]	[●]	[●]	[●]
2.	Yogesh Sachdeva	30,47,057	17.40%	[●]	[●]	[●]	[●]
3.	Kartik Palta	22,09,103	12.61%	[●]	[●]	[●]	[●]
4.	Sukesh Arora	18,28,229	10.44%	[●]	[●]	[●]	[●]
5.	Archna Manocha	17,57,171	10.03%	[●]	[●]	[●]	[●]
6.	Mona Sachdeva	12,18,828	6.96%	[●]	[●]	[●]	[●]
7.	Charu Palta	8,37,941	4.79%	[●]	[●]	[●]	[●]
8.	Siddharth Manocha	5,28,125	3.02%	[●]	[●]	[●]	[●]
Promoter Group							
1.	Ramesh Kumar Dhankani	14,300	0.08%	[●]	[●]	[●]	[●]
2.	Aryan Manocha	4,550	0.03%	[●]	[●]	[●]	[●]
3.	Soumya Manocha	2,730	0.02%	[●]	[●]	[●]	[●]
Additional top 10 Shareholders							
1.	Amit Kumar Saraogi (Murli Janki Legacy Ventures)	3,90,572	2.23%	[●]	[●]	[●]	[●]
2.	Manas Gupta (KRadhe Enterprises)	3,78,937	2.16%	[●]	[●]	[●]	[●]

3.	Neeru Gupta (Radhesh Enterprises)	3,50,233	2.00%	[●]	[●]	[●]	[●]
4.	Amit Gupta (Wealth Creators)	3,50,233	2.00%	[●]	[●]	[●]	[●]
5.	Amit Kumar Goel	97,500	0.56%	[●]	[●]	[●]	[●]
6.	Amit Gupta	87,126	0.50%	[●]	[●]	[●]	[●]
7.	Ritu Bansal	78,000	0.44%	[●]	[●]	[●]	[●]
8.	Sourabh Bansal	78,000	0.44%	[●]	[●]	[●]	[●]
9.	Radha Rani Gupta	53,300	0.30%	[●]	[●]	[●]	[●]
10.	Moongipa Capital Finance Limited	39,000	0.22%	[●]	[●]	[●]	[●]

[^]Includes any transfers of equity shares by existing shareholders after the date of the pre-Offer and price band advertisement until date of prospectus.

^{*}Based on the Offer Price of ₹ [●] and subject to finalization of the Basis of Allotment. To be filled in at Prospectus stage

For further details, see “Capital Structure” on page “82” of the DRHP.

6. Summary of Restated Consolidated Financial Information

The following details of selected financial information are derived from the Restated Consolidated Financial Information for Fiscals 2026, 2025 and 2024:

(in ₹ lakhs except per share data)

Particulars	Fiscal		
	2026	2025	2024
Share Capital	134.71	117.19	117.19
Net Worth ⁽¹⁾	2,990.85	1,314.74	904.64
Total income ⁽²⁾	6,845.21	2,875.54	2,241.83
Profit after tax ⁽³⁾	1,148.61	410.70	160.27
Earnings per share (Basic & diluted) (₹) ⁽⁴⁾	6.99	2.70	1.05
Net Asset Value per Equity Share (₹) ⁽⁵⁾	19.43	8.63	5.94
Total Borrowings ⁽⁶⁾	3,289.77	866.72	829.16
Cash flow from operating activities	(192.89)	416.35	27.01
Cash flow from investing activities	(1224.18)	(412.73)	(53.63)
Cash flow from financing activities	1877.50	(27.21)	(67.94)
Net increase / (decrease) in cash and cash equivalents	460.42	(23.59)	(94.56)

The ratios have been computed as under:

1. Net worth means the aggregate of share capital and other equity
2. Total Income is calculated as Revenue from Operations plus Other Income.
3. PAT is calculated as PAT for the period
4. Basic earnings per share (₹): Profit after tax excluding exceptional items attributable to equity shareholders for the year/period divided by the weighted average no. of equity shares during the respective year/period.
5. Net asset value (NAV) is computed as the closing net worth divided by the closing outstanding number of equity shares.
6. Total borrowings = Restated Consolidated Long-Term Borrowings Plus Restated Consolidated Short-Term Borrowings.

For further details, see “Management’s Discussions and Analysis of Financial Condition and Results of Operations”, “Basis of Offer”, “Restated Consolidated Financial Information” and “Other Financial Information” on pages 280, 121, 241 and 274, respectively of the DRHP.

7. Summary of Key Performance Indicators

Metric	As of and for the Fiscal		
	2026	2025	2024
Revenue From operations (₹ in Lakhs)	6,794.51	2,869.45	2,223.72
Total revenue (₹ in Lakhs)	6,845.21	2,875.54	2,241.83
EBITDA (₹ in Lakhs)	1,692.47	627.82	345.49
EBITDA Margin (%)	24.91%	21.88%	15.54%
Profit after tax (₹ in Lakhs)	1,148.61	410.70	160.27
PAT Margin (%)	16.91%	14.31%	7.21%
Return on Equity (ROE) (%)	35.95%	31.24%	17.72%

Metric	As of and for the Fiscal		
	2026	2025	2024
Debt To Equity Ratio	1.10	0.66	0.92
Interest Coverage Ratio	11.38	8.69	4.52
Return on Capital Employed (ROCE) (%)	34.71%	30.78%	18.42%
Current Ratio	1.68	1.45	2.08
Capital Turnover Ratio	3.18	7.12	4.39

Notes:

- As certified by Surender Kumar Singhal & Co. pursuant to their certificate dated September 29, 2026. The Audit committee in its resolution dated September 29, 2026 has confirmed that the Company has not disclosed any KPIs to any investors at any point of time during the three years preceding the date of this Draft Red Herring Prospectus other than as disclosed in this section.
- Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.
- EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items. EBITDA excludes other income but includes reversal of provision of doubtful debts.
- EBITDA Margin refers to EBITDA during a given period as a percentage of revenue from operations during that period.
- Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes but before other comprehensive income by our revenue from operations.
- Return on equity (RoE) is equal to profit after tax for the year divided by the total equity shareholders' fund including non-controlling interest and is expressed as a percentage.
- Debt to equity ratio is calculated by dividing the debt (excluding lease liabilities) by total equity (which includes issued capital and all other equity reserves excluding).
- Interest Coverage Ratio measures our ability to make interest payments from available earnings and is calculated by dividing EBIT by finance cost payment.
- RoCE (Return on Capital Employed) (%) is calculated as profit before tax plus finance costs divided by Capital employed. Capital employed is worked out as Total assets less current liabilities, intangible assets and long term provisions.
- Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.
- Capital Turnover Ratio quantifies our effectiveness in utilizing our capital of equity shareholders fund and is calculated by dividing our revenue from operations by working capital for the year.

For definitions of the above KPIs, see “Definitions and Abbreviations – Definitions of Key Performance Indicators” on page 01 of the DRHP.

Further, or comparison with the listed peer(s) and more detailed disclosure on such KPIs, see “Basis for Offer Price - VIII. Comparison of financial KPIs of our Company and our listed peer” on page 122 of the DRHP.

8. Risk Factors

Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. Details of our top 10 risk factors are set forth below:

Sr. No.	Description of Risk
1.	We rely on the availability of key raw materials and components, as well as third-party suppliers, for the uninterrupted supply of raw materials and components. We do not have continuing or exclusive arrangements with any supplier, and our top 10 suppliers contribute to 60.56% of our total raw materials and components and supply costs for the Fiscal 2026. The loss of key suppliers or delays in raw material deliveries could adversely impact our business, financial condition, results of operations, and cash flows.
2.	We derive a significant portion of our revenue from certain of our infection control products. If sales volume or price of such products declines in the future, or if we are unable to sell such products for any reason, our business, financial condition, cash flows and results of operations could be adversely affected. Our commercial success is largely dependent upon our ability to strategically diversify our product portfolio. Presently, we deal in a limited number of products and therefore, our ability to diversify and successfully market our products might be limited, which may have an adverse impact on our revenue and profitability.
3.	We generate our major portion of sales from our operations in certain geographical regions of India. Any adverse developments affecting our operations in these regions could have an adverse impact on our revenue and results of operations.
4.	Our business relies on distributors and super-stockists for the sale and distribution of our products. Any inability to establish, maintain, or strengthen relationships with our distributors may have a material adverse effect on our business, financial condition, results of operations, and cash flows.
5.	Any contamination, spoilage, deterioration, mislabeling or improper processing or storage of our products or raw materials, whether actual or perceived, could subject us to statutory or regulatory action, damage our reputation

Sr. No.	Description of Risk
	and adversely affect our business, financial condition, results of operations and cash flows.
6.	Our business is dependent on the performance of the healthcare industry. Economic cyclicity coupled with reduced demand in these other industries, in India or globally, could adversely affect our business, results of operations and financial condition.
7.	Our Company is dependent on a domestic market for its sales and any downturn in it could reduce our sales.
8.	A significant portion of our domestic sales are derived from the North zone, any adverse developments in this market could adversely affect our business.
9.	We have experienced negative operating, investing and financing cash flow. Any operating losses or negative cash flows in the future could adversely affect our results of operations and financial conditions.
10.	We operate our Registered Office, Warehouses and Sale Office that are held by us on leasehold or rented basis. In the event we lose or are unable to renew such leasehold rights, our business, results of operations, financial condition, cash flows and prospects may be adversely affected.

For details, see “Risk Factors” on page 20 of the DRHP.

9. The details of weighted average cost of acquisition of shares for promoters and promoter selling shareholders

Particulars	Number of Equity Shares of face value ₹ 10 held as on date	Weighted average cost of acquisitions per Equity Share (in ₹)	Weighted average cost of acquisition per Equity Share acquired in last 1 year (in ₹)	Weighted average cost of acquisition per Equity Share acquired in last 3 years (in ₹)
Promoter				
Sanjay Manocha	38,08,818	Nil	Nil	Nil
Yogesh Sachdeva	30,47,057	6.15	Nil	6.15
Kartik Palta	22,09,103	6.15	Nil	6.15
Sukesh Arora*	18,28,229	6.15	Nil	6.15
Archna Manocha*	17,57,171	Nil	Nil	Nil
Mona Sachdeva*	12,18,828	6.15	Nil	6.15
Charu Palta*	8,37,941	6.15	Nil	6.15
Siddharth Manocha	5,28,125	2.46	Nil	Nil

As certified by Surender Kumar Singhal & Co. Chartered Accountants, pursuant to their certificate dated September 26, 2026.

*Also the promoter selling shareholders.

Weighted average cost of acquisition of Equity Shares transacted in last one year, 18 months and three years preceding the date of this Draft Red Herring Prospectus

Weighted average cost of acquisition of Equity Shares transacted in last one year, 18 months and three years preceding the date of this Draft Red Herring Prospectus is set out below:

Period	Weighted average cost of acquisition per Equity Share (in ₹)^	Cap Price is ‘x’ times the weighted average cost of acquisition^	Range of acquisition price per Equity Share: lowest price – highest price (in ₹)
Last one year preceding the date of this Draft Red Herring Prospectus	3.24	[●]	0-928
Last 18 months preceding the date of this Draft Red Herring Prospectus	Nil	[●]	0-928
Last three years preceding the date of this Draft Red Herring Prospectus	Nil	[●]	0-928

As certified by Surender Kumar Singhal & Co., Chartered Accountants, pursuant to their certificate dated September 26, 2026.

^ To be updated in the Prospectus following finalisation of Cap Price, as per the finalised Price Band.

For details, see “Capital Structure” on page 82 of the DRHP.

10. Board of Directors and Key Managerial Personnel

The names and designations of the members of the Board of Directors and Key Managerial Personnel are set forth below:

Sr. No.	Name	Designation
Board of Directors		
1.	Sanjay Manocha*	Managing Director
2.	Archana Manocha*	Executive Director and Chief Financial Officer
3.	Yogesh Sachdeva	Whole- Time Director
4.	Kartik Palta	Whole- Time Director
5.	Prashant Jain	Non-Executive Director
6.	Neelam Sachdeva	Independent Director
7.	Rajiv Jasuja	Independent Director
8.	Vishal Gupta	Independent Director
Key Managerial Personnel		
1.	Vidushi	Company Secretary and Compliance Officer

*Also, Key Managerial Personnel

For further details in relation to our Board of Directors and Key Managerial Personnel, see “Our Management” on page 214 of the DRHP

11. Auditor’s Qualifications

Except as stated in “Management’s Discussions and Analysis of Financial Condition and Results of Operations – Reservations, Qualifications, and Adverse Remarks by Auditors” on page 280 of the DRHP, there are no qualifications of the Statutory Auditors which have not been given effect to in the Restated Consolidated Financial Statements.

12. Summary table of outstanding litigations

A summary of such outstanding criminal proceedings, taxation proceedings, actions taken by statutory and regulatory authorities, and other material pending litigation as on the date of this Draft Red Herring Prospectus and as disclosed in section “Outstanding Litigation and Material Developments” on page 289 of the DRHP, is set out below:

Outstanding Litigations	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchange	Material Civil Litigation	Amount involved
Company						
By the Company	Nil	Nil	Nil	Nil	1	*
Against the Company	Nil	Nil	Nil	Nil	Nil	-
Subsidiary						
By the Company	Nil	Nil	Nil	Nil	Nil	-
Against the Company	Nil	Nil	Nil	Nil	Nil	-
Promoters						
By the Promoters	Nil	Nil	Nil	Nil	Nil	-
Against the Promoters	Nil	Nil	Nil	Nil	Nil	-
Directors						
By the Directors	Nil	Nil	Nil	Nil	Nil	-
Against the Directors	Nil	Nil	Nil	Nil	Nil	-
SMPs and KMPs						
By the SMPs and KMPs	Nil	Nil	Nil	Nil	Nil	-
Against the SMPs and KMPs	Nil	Nil	Nil	Nil	Nil	-
Litigation involving our Group Company which may have material impact on our Company						
Outstanding Litigation which may have material impact on our Company	Nil	Nil	Nil	Nil	Nil	-

**Includes a proceeding pertain to writ petitions and claim amount does not arise in these matter.*

For further details of the outstanding litigation proceedings, see “*Outstanding Litigation and Material Developments*” beginning on page 289 of the DRHP.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. In particular, the Equity Shares offered in the Offer have not been and will not be registered, listed or otherwise qualified in any jurisdiction except India and may not be offered or sold to persons outside of India except in compliance with the applicable laws of each such jurisdiction. In particular, the Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. The Equity Shares offered in the Offer are being offered and sold only outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act.

Persons outside India are ineligible to Bid for Equity Shares in the Offer unless they have received the preliminary offering memorandum for the Offer, which will comprise the Red Herring Prospectus and the preliminary international wrap, which contains the selling restrictions for the Offer outside India.